Study #2023-0010
A Phase I study of the treatment of recurrent malignant Glioma with rQNestin34.5v.2, a genetically engineered HSV-1 Virus, and immunomodulation with Cyclophosphamide (Dana Farber Cancer Institute/ Brigham and Women's Hospital)
MD Anderson Study Status
Enrolling
Treatment Agent
rQNestin, Cyclophosphamide
Description
This research study is evaluating an investigational drug, an oncolytic virus called rQNestin34.5v.2. This research study is a Phase I clinical trial, which tests the safety of an investigational drug and also tries to define the appropriate dose of the investigational drug as a possible treatment for this diagnosis of recurrent or progressive brain tumor.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Malignant Glioma of Brain, Astrocytoma, Malignant Astrocytoma, Oligodendroglioma, Anaplastic Oligodendroglioma of Brain (Diagnosis), Mixed Oligo-Astrocytoma, Ependymoma, Ganglioglioma, Pylocytic/Pylomyxoid Astrocytoma, Brain Tumor, Glioma, Brain Cancer, Glioblastoma, Glioblastoma Multiforme
Study phase:
Phase I
Physician name:
Yon Son Betty Kim
Department:
Neurosurgery
For general questions about clinical trials:
1-844-996-5012
Help #EndCancer
Give Now
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.